| Literature DB >> 34930228 |
Tom Oluoch1, Ronald Cornet2, Jacques Muthusi3, Abraham Katana3, Davies Kimanga3, Daniel Kwaro4, Nicky Okeyo4, Ameen Abu-Hanna2, Nicolette de Keizer2.
Abstract
BACKGROUND: Loss to follow-up (LFTU) among HIV patients remains a major obstacle to achieving treatment goals with the risk of failure to achieve viral suppression and thereby increased HIV transmission. Although use of clinical decision support systems (CDSS) has been shown to improve adherence to HIV clinical guidance, to our knowledge, this is among the first studies conducted to show its effect on LTFU in low-resource settings.Entities:
Keywords: Decision support systems; Electronic medical records; HIV; Loss to follow-up; Low resource country; Quality of care
Mesh:
Substances:
Year: 2021 PMID: 34930228 PMCID: PMC8686234 DOI: 10.1186/s12911-021-01718-0
Source DB: PubMed Journal: BMC Med Inform Decis Mak ISSN: 1472-6947 Impact factor: 2.796
Fig. 1The study profile
Baseline characteristics of CDSS art patients by site type, n = 5901
| Characteristic | Control | Intervention | Total | P value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Unweighted n | Weighted % | 95% CI | Unweighted n | Weighted % | 95% CI | Unweighted N | Weighted % | 95% CI | ||
| < .001 | ||||||||||
| < 10 years | 303 | 8.4 | (7.5–9.3) | 170 | 7.4 | (6.3–8.4) | 473 | 8 | (7.3–8.7) | |
| 10–19 years | 128 | 3.6 | (3.0–4.2) | 82 | 3.6 | (2.8–4.3) | 210 | 3.6 | (3.1–4.0) | |
| 20–29 years | 1065 | 29.6 | (28.1–31.1) | 638 | 27.7 | (25.8–29.5) | 1703 | 28.9 | (27.7–30.0) | |
| 30–39 years | 1169 | 32.5 | (31.0–34.0) | 766 | 33.2 | (31.3–35.1) | 1935 | 32.8 | (31.6–34.0) | |
| 40–49 years | 610 | 17 | (15.7–18.2) | 359 | 15.6 | (14.1–17.0) | 969 | 16.4 | (15.5–17.4) | |
| 50–59 years | 251 | 7 | (6.1–7.8) | 210 | 9.1 | (7.9–10.3) | 461 | 7.8 | (7.1–8.5) | |
| 60 + years | 69 | 1.9 | (1.5–2.4) | 81 | 3.5 | (2.8–4.3) | 150 | 2.5 | (2.1–2.9) | |
| Total | 3595 | 100 | (–) | 2306 | 100 | (–) | 5901 | 100 | (–) | |
| 0.055 | ||||||||||
| Male | 1311 | 36.5 | (34.9–38.0) | 898 | 38.9 | (37.0–40.9) | 2209 | 37.4 | (36.2–38.7) | |
| Female | 2284 | 63.5 | (62.0–65.1) | 1408 | 61.1 | (59.1–63.0) | 3692 | 62.6 | (61.3–63.8) | |
| Total | 3595 | 100 | (–) | 2306 | 100 | (–) | 5901 | 100 | (–) | |
| < .001 | ||||||||||
| Missing | 309 | 8.6 | (7.7–9.5) | 202 | 8.8 | (7.6–9.9) | 511 | 8.7 | (7.9–9.4) | |
| Married | 1934 | 53.8 | (52.2–55.4) | 1163 | 50.4 | (48.4–52.5) | 3097 | 52.5 | (51.2–53.8) | |
| Divorced/separated | 138 | 3.8 | (3.2–4.5) | 133 | 5.8 | (4.8–6.7) | 271 | 4.6 | (4.1–5.1) | |
| Widow | 673 | 18.7 | (17.4–20.0) | 401 | 17.4 | (15.8–18.9) | 1074 | 18.2 | (17.2–19.2) | |
| Single | 541 | 15 | (13.9–16.2) | 407 | 17.6 | (16.1–19.2) | 948 | 16.1 | (15.1–17.0) | |
| Total | 3595 | 100 | (–) | 2306 | 100 | (–) | 5901 | 100 | (–) | |
| < .001 | ||||||||||
| Missing | 846 | 23.5 | (22.1–24.9) | 727 | 31.5 | (29.6–33.4) | 1573 | 26.7 | (25.5–27.8) | |
| < 200 | 1592 | 44.3 | (42.7–45.9) | 900 | 39 | (37.0–41.0) | 2492 | 42.2 | (41.0–43.5) | |
| 200–349 | 984 | 27.4 | (25.9–28.8) | 620 | 26.9 | (25.1–28.7) | 1604 | 27.2 | (26.0–28.3) | |
| 350–500 | 78 | 2.2 | (1.7–2.6) | 33 | 1.4 | (0.9–1.9) | 111 | 1.9 | (1.5–2.2) | |
| ≥ 500 | 95 | 2.6 | (2.1–3.2) | 26 | 1.1 | (0.7–1.6) | 121 | 2.1 | (1.7–2.4) | |
| Total | 3595 | 100 | (–) | 2306 | 100 | (–) | 5901 | 100 | (–) | |
| 0.105 | ||||||||||
| Missing | 193 | 5.4 | (4.6–6.1) | 105 | 4.6 | (3.7–5.4) | 298 | 5 | (4.5–5.6) | |
| WHO I | 707 | 19.7 | (18.4–21.0) | 487 | 21.1 | (19.5–22.8) | 1194 | 20.2 | (19.2–21.3) | |
| WHO II | 1056 | 29.4 | (27.9–30.9) | 645 | 28 | (26.1–29.8) | 1701 | 28.8 | (27.7–30.0) | |
| WHO III | 1550 | 43.1 | (41.5–44.7) | 993 | 43.1 | (41.0–45.1) | 2543 | 43.1 | (41.8–44.4) | |
| WHO IV | 89 | 2.5 | (2.0–3.0) | 76 | 3.3 | (2.6–4.0) | 165 | 2.8 | (2.4–3.2) | |
| Total | 3595 | 100 | (–) | 2306 | 100 | (–) | 5901 | 100 | (–) | |
| < .001 | ||||||||||
| Nevirapine | 3084 | 85.8 | (84.6–86.9) | 1803 | 78.2 | (76.5–79.9) | 4887 | 82.8 | (81.9–83.8) | |
| Efavirenz | 489 | 13.6 | (12.5–14.7) | 465 | 20.2 | (18.5–21.8) | 954 | 16.2 | (15.2–17.1) | |
| Other | 22 | 0.6 | (0.4–0.9) | 38 | 1.6 | (1.1–2.2) | 60 | 1 | (0.8–1.3) | |
| Total | 3595 | 100 | (–) | 2306 | 100 | (–) | 5901 | 100 | (–) | |
| 0.012 | ||||||||||
| Missing | 3112 | 86.6 | (85.4–87.7) | 1934 | 83.9 | (82.4–85.4) | 5046 | 85.5 | (84.6–86.4) | |
| Satisfactory | 480 | 13.4 | (12.2–14.5) | 368 | 16 | (14.5–17.5) | 848 | 14.4 | (13.5–15.3) | |
| Unsatisfactory | 3 | 0.1 | (0.0–0.2) | 4 | 0.2 | (0.0–0.3) | 7 | 0.1 | (0.0–0.2) | |
| Total | 3595 | 100 | (–) | 2306 | 100 | (–) | 5901 | 100 | (–) | |
Factors associated with lost to follow-up over time among ART patients, N = 5901
| Characteristic | Unadjusted odds ratios | Adjusted odds ratios | ||||
|---|---|---|---|---|---|---|
| OR (95% CI) | P value | Global p value | OR (95% CI) | P value | Global p value | |
| Control intervention | 0.70 (0.65–0.76) | < .001 | < .001 | 0.70 (0.65–0.77) | < .001 | < .001 |
| < 10 years | ||||||
| 10–19 years | 1.41 (1.13–1.77) | 0.003 | 0.127 | 1.2 (0.95–1.5) | 0.126 | 0.187 |
| 20–29 years | 0.88 (0.76–1.02) | 0.087 | 0.88 (0.75–1.04) | 0.129 | ||
| 30–39 years | 0.94 (0.82–1.08) | 0.393 | 0.94 (0.8–1.12) | 0.499 | ||
| 40–49 years | 1.14 (0.98–1.33) | 0.093 | 1.01 (0.85–1.21) | 0.872 | ||
| 50–59 years | 0.92 (0.77–1.1) | 0.376 | 0.9 (0.74–1.11) | 0.335 | ||
| 60 + years | 1.12 (0.86–1.46) | 0.4 | 1.11 (0.83–1.47) | 0.482 | ||
| Male | ||||||
| Female | 1.01 (0.94–1.09) | 0.713 | 0.713 | 0.95 (0.87–1.03) | 0.193 | 0.193 |
| Divorced/Separated | ||||||
| Married | 1.55 (1.25–1.92) | < .001 | < .001 | 1.34 (1.11–1.61) | 0.002 | < .001 |
| Single | 2.97 (2.37–3.72) | < .001 | 1.39 (1.13–1.72) | 0.002 | ||
| Widow | 1.56 (1.25–1.94) | < .001 | 1.43 (1.17–1.74) | 0.001 | ||
| < 200 | ||||||
| 200–350 | 1.49 (1.36–1.65) | < .001 | 0.678 | |||
| 350–500 | 1.07 (0.82–1.39) | 0.633 | ||||
| ≥ 500 | 0.98 (0.75–1.28) | 0.853 | ||||
| WHO IV | ||||||
| WHO I | 2.75 (2.13–3.55) | < .001 | < .001 | 1.24 (0.98–1.58) | 0.076 | 0.026 |
| WHO II | 1.71 (1.33–2.2) | < .001 | 1.36 (1.08–1.72) | 0.01 | ||
| WHO III | 1.35 (1.05–1.73) | 0.019 | 1.27 (1.01–1.6) | 0.044 | ||
| Other | ||||||
| Efavirenz | 1.90 (1.09–3.32) | 0.024 | < .001 | 1.83 (1.04–3.21) | 0.036 | < .001 |
| Nevirapine | 3.18 (1.84–5.51) | < .001 | 2.82 (1.62–4.91) | < .001 | ||
Fig. 2Time from study enrollment to documentation of first LTFU